Edwin Calderon, PA
Physician Assistant · New York, NYNPI 1437350873
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 506 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Viiv Healthcare Company at 35.7% of the total. 2025 is the largest year on record at $4,009, 2.1 times the $1,937 reported in 2021. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$5K
- Gilead$2K
- Johnson & Johnson$2K
- Theratechnologies Inc.$1K
- Merck$851
- EMD Serono, Inc.$531
- plus $2K from 18 others
Across 5 payments — averaging $8954.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Theratechnologies Inc.$45K
What the payments were for
- Consulting fees$5004%
- Food & beverage$13,04795%
- Education$2182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 176 | $4,911 |
| Gilead | 115 | $2,220 |
| Johnson & Johnson(2 entities) | 53 | $1,503 |
| Theratechnologies Inc. | 25 | $1,426 |
| Merck | 27 | $851 |
| EMD Serono, Inc. | 24 | $531 |
| Janssen Scientific Affairs, LLC | 11 | $518 |
| Janssen Products, LP | 3 | $310 |
| AbbVie | 11 | $255 |
| Otsuka America Pharmaceutical, Inc. | 16 | $242 |
| AstraZeneca | 10 | $207 |
| Bausch Health US, LLC | 8 | $181 |
| Antares Pharma, Inc. | 3 | $87 |
| Exact Sciences | 3 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Lilly USA, LLC | 3 | $70 |
| Kowa Pharmaceuticals America, Inc. | 3 | $53 |
| Paratek Pharmaceuticals, Inc. | 2 | $48 |
| Octapharma USA, Inc. | 2 | $47 |
| Napo Pharmaceuticals Inc | 2 | $46 |
| Halozyme Inc | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,765 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 59 | $239,550 |
| DescovyEmtricitabine/Tenofov Alafenam | 56 | $123,428 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 25 | $97,015 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 15 | $50,646 |
| TivicayDolutegravir Sodium | 18 | $39,214 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $33,856 |
| Isentress HdRaltegravir Potassium | 12 | $24,090 |
| XareltoRivaroxaban | 21 | $11,877 |
| XyostedTestosterone Enanthate | 14 | $8,772 |
| SynthroidLevothyroxine Sodium | 13 | $555 |
| Atorvastatin Calcium | 60 | $454 |
| Omega-3 Acid Ethyl Esters | 16 | $434 |
| Bupropion XlBupropion Hcl | 25 | $317 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $240 |
| Enalapril Maleate | 23 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $2,220 | $459,993140 claims |
| Viiv Healthcare CompanyTivicay, Dovato | $4,911 | $73,07030 claims |
| MerckIsentress Hd | $851 | $24,09012 claims |
| Johnson & JohnsonXarelto | $1,503 | $11,87721 claims |
| Antares Pharma, Inc.Xyosted | $87 | $8,77214 claims |
| AbbVieSynthroid | $255 | $55513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in New York
- Kristyl Cuenca-SiskoNew York$478K
- Cameron KiserNew York$225K
- Mervat FalahNew York$143K
- Marlene TaylorNew York$109K
- Natalie TafelNew York$77K
- Jonathan YehNew York$57K
- Emily ElbogenNew York$49K
- Jaclyn ChurchillNew York$48K
- Russell BrandweinNew York$44K
- Michelle MelchiorreNew York$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.